New England Journal of Medicine FEBRUARY 10, 2022

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Jayk Bernal A, et al.

Bottom Line

The MOVe-OUT trial demonstrated that early treatment with oral molnupiravir significantly reduced the risk of hospitalization or death in high-risk, unvaccinated adults with mild-to-moderate COVID-19.

Key Findings

1. In the full analysis, 6.8% (48/709) of participants in the molnupiravir group were hospitalized or died through day 29, compared to 9.7% (68/699) in the placebo group, resulting in an absolute risk reduction of 3.0 percentage points (95% CI, -5.9 to -0.1).
2. The risk of hospitalization or death was reduced by 30% (relative risk, 0.70; 95% CI, 0.49 to 0.99) with molnupiravir compared to placebo.
3. One death was reported in the molnupiravir group versus nine deaths in the placebo group through day 29.
4. The incidence of adverse events was similar between the groups, occurring in 30.4% of the molnupiravir arm and 33.0% of the placebo arm.

Study Design

Design
RCT
Double-Blind
Sample
1,433
Patients
Duration
29 d
Median
Setting
Multicenter, global
Population Nonhospitalized, unvaccinated adults with mild-to-moderate COVID-19 and at least one risk factor for severe disease.
Intervention 800 mg of molnupiravir orally twice daily for 5 days.
Comparator Placebo administered twice daily for 5 days.
Outcome Proportion of participants who were hospitalized for any cause or died through day 29.

Study Limitations

The treatment effect observed in the full population (30% reduction) was substantially lower than the 48% reduction estimated in the prespecified interim analysis.
There was an unexplained imbalance in gender distribution between the treatment arms.
Subgroup analyses revealed that in certain populations, such as those with previous SARS-CoV-2 infection or low baseline viral load, the point estimate favored the placebo group.
The study was conducted exclusively in unvaccinated individuals, limiting the generalizability of findings to vaccinated populations.

Clinical Significance

The trial supported the emergency use authorization of molnupiravir as an oral therapeutic option for high-risk, unvaccinated outpatients to prevent progression to severe COVID-19. However, the modest magnitude of benefit and variable efficacy observed across subgroups prompted careful consideration regarding its place in therapy compared to more potent alternatives.

Historical Context

During the COVID-19 pandemic, there was an urgent need for easily administered, oral antiviral treatments for outpatient use to reduce healthcare system strain. Molnupiravir, a nucleoside analog that works by inducing viral RNA mutagenesis, was one of the first oral antiviral agents developed and tested specifically for this purpose in high-risk populations.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

What is the unique biochemical mechanism of action of molnupiravir, and how does its status as a ribonucleoside analog lead to the 'error catastrophe' in SARS-CoV-2 replication?

Key Response

Molnupiravir is a prodrug of the ribonucleoside analog N4-hydroxycytidine. Once phosphorylated into a triphosphate form, it is used as a substrate by the viral RNA-dependent RNA polymerase (RdRp). Crucially, it can base-pair with either guanine or adenine. This ambiguity results in 'lethal mutagenesis,' where the viral genome accumulates so many errors during replication that it becomes non-functional, a process distinct from the chain termination mechanism used by drugs like remdesivir.

Resident
Resident

In the context of the MOVe-OUT trial results, which specific patient criteria must be met for a patient to be considered a candidate for molnupiravir under current clinical standards, and why is the timing of administration critical?

Key Response

The trial targeted nonhospitalized adults with mild-to-moderate COVID-19, at least one risk factor for severe illness (e.g., obesity, age >60, diabetes), and symptom onset within 5 days. Timing is critical because viral replication is highest in the early phase of the illness; once the inflammatory/host-response phase dominates, antiviral efficacy significantly diminishes, as reflected in the trial's exclusion of patients already requiring hospitalization.

Fellow
Fellow

The MOVe-OUT trial demonstrated a 30% relative risk reduction in hospitalization or death, yet the interim analysis originally suggested 50%. How should a clinician integrate this 'shrinking' effect size and the emergence of variants like Omicron when comparing molnupiravir to nirmatrelvir/ritonavir?

Key Response

The decrease from interim to final analysis results (regression to the mean) and the transition from Delta to Omicron variants have shifted the clinical landscape. Fellows must recognize that while molnupiravir remains an option, its lower efficacy (30%) compared to nirmatrelvir/ritonavir (~89%) and the PANORAMIC trial data (showing limited benefit in vaccinated populations) usually relegates it to a second or third-line agent, particularly useful only when significant drug-drug interactions preclude the use of ritonavir-boosted agents.

Attending
Attending

Given the mechanism of 'lethal mutagenesis,' what are the specific reproductive safety concerns and counseling requirements you must address when prescribing molnupiravir to a patient of childbearing potential?

Key Response

Due to theoretical concerns that molnupiravir could be incorporated into human DNA (mutagenicity), it is not recommended for use during pregnancy. Attending physicians must ensure that females of childbearing potential use reliable contraception during treatment and for 4 days after the final dose, and that males use contraception for at least 3 months after the final dose to minimize potential risks to fetal development or germ cells.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

The MOVe-OUT trial utilized a composite primary endpoint of hospitalization or death. Critique the statistical implications of using this composite in an era of changing hospitalization thresholds and the impact of the trial's early termination for efficacy on the reported point estimate.

Key Response

Composite endpoints can be driven by the more frequent but less severe component (hospitalization). If the criteria for 'hospitalization' changed during the trial due to healthcare strain, the endpoint's stability is threatened. Furthermore, stopping a trial early for efficacy often leads to an overestimation of the treatment effect; the subsequent 'dilution' of efficacy in the final MOVe-OUT analysis illustrates the importance of analyzing the full cohort to obtain a more precise and potentially more modest estimate of clinical benefit.

Journal Editor
Journal Editor

If you were the primary reviewer for the MOVe-OUT manuscript, how would you address the potential for selection bias regarding the study's inclusion of only unvaccinated participants, and how does this affect the manuscript's external validity?

Key Response

The exclusion of vaccinated individuals creates a 'best-case scenario' for observing a treatment effect because the baseline risk in the placebo group is high. An editor would flag that while the internal validity is strong for the specific cohort, the results cannot be easily extrapolated to a highly vaccinated or previously infected population where the absolute risk reduction (ARR) would likely be much lower, potentially rendering the Number Needed to Treat (NNT) clinically or economically unattractive.

Guideline Committee
Guideline Committee

How does the NIH COVID-19 Treatment Guidelines' current hierarchical ranking of molnupiravir reflect the MOVe-OUT data relative to the EPIC-HR trial, and under what specific circumstances should its recommendation be upgraded?

Key Response

The NIH guidelines currently list molnupiravir as the last-choice antiviral, to be used only when nirmatrelvir/ritonavir or remdesivir are not available or clinically appropriate. This hierarchy is based on the 30% relative risk reduction in MOVe-OUT compared to the higher efficacy seen with other agents. It should only be 'upgraded' in clinical scenarios involving severe drug-drug interactions with ritonavir (e.g., certain anticonvulsants or antiarrhythmics) where intravenous remdesivir is logistically impossible to administer.

Clinical Landscape

Noteworthy Related Trials

2021

EPIC-HR Trial

n = 2,246 · NEJM

Tested

Nirmatrelvir plus ritonavir

Population

Nonhospitalized symptomatic adults with COVID-19 at high risk for progression

Comparator

Placebo

Endpoint

Incidence of COVID-19-related hospitalization or death from any cause through day 28

Key result: Nirmatrelvir plus ritonavir reduced the risk of COVID-19-related hospitalization or death by 89% compared to placebo.
2022

PRINCIPLE Trial

n = 2,579 · Lancet

Tested

Inhaled budesonide

Population

Older adults at high risk for complications from COVID-19 managed in primary care

Comparator

Usual care

Endpoint

Time to self-reported recovery

Key result: Inhaled budesonide shortened the time to recovery by a median of 3 days among nonhospitalized adults.
2022

TOGETHER Trial

n = 3,515 · Lancet Glob Health

Tested

Fluvoxamine

Population

High-risk symptomatic outpatients with early diagnosed COVID-19

Comparator

Placebo

Endpoint

Retention in an emergency setting or hospitalization due to COVID-19

Key result: Fluvoxamine treatment reduced the composite risk of emergency room retention or hospitalization for COVID-19.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis